Last month (January 15, 2026) Germany’s Bundesrag held a debate on the hotly contested amendments aimed at significantly restricting medical cannabis prescriptions, and potentially transforming the industry.
Last week, Business of Cannabis reported on the publication of Germany’s first official evaluation of its Recreational Cannabis Act (KCanG) and the early data suggesting limited social and health impacts from legalisation.
Germany’s CanG bill looks to be back on track Germany’s landmark CanG bill is now expected to pass through the Federal Parliament (Bundestag) this month, putting it back on track to come into effect by April 1.
Germany’s Cannabis Act (CanG) is entering increasingly uncertain territory as support within the coalition’s largest party crumbles, and criticism of the bill begins to surface on multiple fronts.
Germany’s CanG bill has been delayed yet again, just days after reports emerged that the coalition parties and Ministry of Health had come to an agreement on some of its most contentious points.
EARLIER this month news broke that recent analysis conducted by the Bundestag’s scientific service suggested the creation of a legal recreational cannabis market could contravene a number of European treaties which Germany had signed.
